1. Clinical & Scientific Overview
Sevelamer Carbonate & Calcium Polystyrene Sulfonate / Sodium Zirconium Cyclosilicate (TIP-MED-000204, Reference Code [10.20]) is classified under
Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.20], p. 136): Sevelamer Carbonate: Renvela (Sanofi), Foseal (Emcure), Sevcar (Emcure), Acutrol-C. Calcium Polystyrene Sulfonate (CPS): K-Bind (Steadfast — 15 g Sachet), Kayexalate. Sodium Zirconium Cyclosilicate (SZC): Lokelma (AstraZeneca — 5 g / 10 g Sachet) — Strengths & Dosage Forms: Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g
Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g
3. Mechanism of Action & Pharmacodynamics
Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H) for Sevelamer: Control of Hyperphosphataemia (Serum Phosphate >4.5–5.5 mg/dL) in CKD Stage 4–5 and dialysis (non-absorbed, calcium-free polymer that binds dietary phosphate in the gut without causing hypercalcaemia; also lowers LDL-C by 15–30%!). CPS (K-Bind) & SZC (Lokelma): Treatment of Hyperkalaemia (Serum K+ >5.0–5.5 mEq/L) in CKD or patients on RAASi.
4. Therapeutic Indications & Evidence-Supported Uses
- Sevelamer: Control of Hyperphosphataemia (Serum Phosphate >4
- 5 mg/dL) in CKD Stage 4–5 and dialysis (non-absorbed, calcium-free polymer that binds dietary phosphate in the gut without causing hypercalcaemia
- also lowers LDL-C by 15–30%!)
- CPS (K-Bind) & SZC (Lokelma): Treatment of Hyperkalaemia (Serum K+ >5
- 5 mEq/L) in CKD or patients on RAASi
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Sevelamer Carbonate: Start 400–800 mg PO THREE TIMES DAILY WITH MEALS (titrate to 800–1600 mg TDS with meals to keep Serum Phosphate 3.5–5.5 mg/dL). K-Bind (CPS): 15 g sachet suspended in 60–100 mL water PO 1–3 times daily. SZC (Lokelma): Correction: 10 g TDS x 48h; Maintenance: 5–10 g OD
Administration & Meal Timing: OPPOSITE TIMING RULES: (1) Sevelamer (Foseal/Sevcar) MUST BE SWALLOWED WHOLE RIGHT WITH MEALS (taking Sevelamer on an empty stomach is 100% useless! Never crush or chew Sevelamer tablets as they swell in saliva and cause choking!). (2) Separate K-Bind and Lokelma by AT LEAST 2–3 HOURS from all other oral medications! | Sevelamer: WITH Breakfast, Lunch & Dinner. K-Bind / Lokelma: Separated >=2–3h from other drugs
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
7. Contraindications, Precautions & High-Risk Warnings
- Sevelamer CONTRAINDICATED in hypophosphataemia and bowel obstruction/ileus. K-Bind (CPS) CONTRAINDICATED in Serum K+ <5.0 mEq/L, obstructive bowel disease, postoperative ileus, and severe constipation — NEVER mix SPS/CPS with Sorbitol (causes fatal colonic necrosis and intestinal perforation!)!
Key Clinical Precautions: Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
8. Adverse Effects Profile
- Sevelamer: Constipation, nausea, dyspepsia, flatulence. K-Bind: Constipation, faecal impaction, nausea, hypokalaemia, hypercalcaemia. Lokelma: Mild ankle oedema
- Sevelamer: Bowel obstruction/perforation, oesophageal obstruction if dry-swallowed or chewed; K-Bind/SPS: Fatal Colonic Necrosis / Intestinal Perforation (especially if constipated!), severe hypokalaemia
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- BROAD GI DRUG BINDING: Both Sevelamer and Potassium-binding resins bind oral medications in the gut — separate Ciprofloxacin, Levofloxacin, Levothyroxine (space >=4h!), Mycophenolate (MMF), Tacrolimus, Cyclosporine, Dabigatran, Digoxin, and Lithium by AT LEAST 2–3 HOURS before or after Sevelamer or K-Bind/Lokelma!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: FOUR VITAL CKD COUNTER RULES: (1) Take Foseal/Sevcar (Sevelamer) right WITH your meals and swallow the large tablet whole with water (never chew it, and skip it if you skip a meal); (2) Mix K-Bind sachet in plain water (NEVER fruit juice/coconut water!) and report constipation immediately; (3) Space Thyroid tablets (Thyronorm), Ciprofloxacin, or transplant drugs at least 3–4 hours away from Sevelamer and K-Bind
- Meal & Clock Timing Instruction: OPPOSITE TIMING RULES: (1) Sevelamer (Foseal/Sevcar) MUST BE SWALLOWED WHOLE RIGHT WITH MEALS (taking Sevelamer on an empty stomach is 100% useless! Never crush or chew Sevelamer tablets as they swell in saliva and cause choking!). (2) Separate K-Bind and Lokelma by AT LEAST 2–3 HOURS from all other oral medications! (Sevelamer: WITH Breakfast, Lunch & Dinner. K-Bind / Lokelma: Separated >=2–3h from other drugs)
- Missed Dose Protocol: Sevelamer: If forgotten during a meal, skip it (never take between meals!). K-Bind: Check K+ before repeating
- Geriatric Dispensing Pearl: Ensure older CKD patients have regular bowel movements before giving K-Bind (CPS) to prevent faecal impaction and colonic necrosis
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.20] (p. 136)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.18] Oral Potassium Chloride & Potassium Citrate Solutions — Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelat
- [10.19] Sodium Bicarbonate (Oral Enteric/Uncoated for CKD Metabolic Acidosis) — Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic
- [10.14]-C119 Alfacalcidol — Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalcif
- [10.18]-C126 Oral Potassium Citrate Solution — Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelat